Editas Medicine Inc EDIT.OQ EDIT.O is expected to show a fall in quarterly revenue when it reports results on March 5 for the period ending December 31 2024
The Cambridge Massachusetts-based company is expected to report a 46.3% decrease in revenue to $32.23 million from $60.05 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 36 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 9 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Editas Medicine Inc is $3.50, above its last closing price of $1.92.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.72 | -0.75 | -0.75 | Met | -0.4 |
Jun. 30 2024 | -0.73 | -0.70 | -0.82 | Missed | -16.6 |
Mar. 31 2024 | -0.66 | -0.66 | -0.76 | Missed | -14.3 |
Dec. 31 2023 | -0.60 | -0.54 | -0.23 | Beat | 57.6 |
Sep. 30 2023 | -0.56 | -0.57 | -0.55 | Beat | 3.2 |
Jun. 30 2023 | -0.76 | -0.76 | -0.56 | Beat | 26.6 |
Mar. 31 2023 | -0.78 | -0.78 | -0.71 | Beat | 9.4 |
Dec. 31 2022 | -0.80 | -0.80 | -0.88 | Missed | -9.7 |
This summary was machine generated March 3 at 13:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。